Abionyx Pharma (LTS:0RAG) Long-Term Debt: €1.96 Mil (As of Dec. 2025)


LTS:0RAG Abionyx Pharma LTS:0RAG
29 GF Score
Price €1.90
GF Value €0.85
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Long-Term Debt?

Abionyx Pharma LTS:0RAG 29 Long-Term Debt is €1.96 Mil as of Dec. 2025. GuruFocus rates LTS:0RAG with a GF Score™ of 29/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Abionyx Pharma's Long-Term Debt for the quarter that ended in Dec. 2025 was €1.96 Mil.

Abionyx Pharma's quarterly Long-Term Debt increased from Dec. 2024 (€0.61 Mil) to Jun. 2025 (€2.11 Mil) but then declined from Jun. 2025 (€2.11 Mil) to Dec. 2025 (€1.96 Mil).

Abionyx Pharma's annual Long-Term Debt declined from Dec. 2023 (€1.10 Mil) to Dec. 2024 (€0.61 Mil) but then increased from Dec. 2024 (€0.61 Mil) to Dec. 2025 (€1.96 Mil).

Abionyx Pharma  (LTS:0RAG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Abionyx Pharma Long-Term Debt Related Terms

Abionyx Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma Long-Term Debt Chart

Abionyx Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.65 1.42 1.10 0.61 1.96

Abionyx Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.86 0.61 2.11 1.96
LTS:0RAG
29GF Score
Abionyx Pharma LTS:0RAG
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €1.96 Mil mean?
Abionyx Pharma (LTS:0RAG) has a Long-Term Debt of €1.96 Mil as of Dec. 2025.
Is Abionyx Pharma's Long-Term Debt too high?
Abionyx Pharma's current Long-Term Debt is €1.96 Mil. Overall, Abionyx Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Long-Term Debt compare to VRTX and REGN?
Abionyx Pharma's Long-Term Debt of €1.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Abionyx Pharma's current Long-Term Debt is €1.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €1.90 — trading 123.3% above its estimated fair value. The current Long-Term Debt is €1.96 Mil. Abionyx Pharma's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current Long-Term Debt is €1.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.90 is trading 123.3% above its estimated GF Value™ of €0.85. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0RAG:

  • Long-Term Debt: €1.96 Mil
  • GF Value™: €0.85 vs. price of €1.90 (123.3% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Other Exchanges ABNX:France609:Germany
Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
29GF Score

Get the complete analysis for LTS:0RAG

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.90
Price
€0.85
GF Value